Theriva™ biologics reports second quarter 2023 operational highlights and financial results

- initiated dosing at u.s. sites for virage, the phase 2b clinical trial of vcn-01 in combination with chemotherapy for pancreatic ductal adenocarcinoma

TOVX Ratings Summary

TOVX Quant Ranking